EGFR and non-small cell lung carcinoma: The first line Erbitux in lung cancer (FLEX) study was a phase III clinical trial assessing the effects of cetuximab plus first-line chemotherapy (cisplatin and vinorelbine) in advanced EGFR positive NSCLC cases.